Stockscreener 앱 받기
19.21
0.10%
0.02
전일 마감가:
$19.19
열려 있는:
$19.63
하루 거래량:
773.14K
Relative Volume:
0.79
시가총액:
$1.41B
수익:
-
순이익/손실:
$-230.32M
주가수익비율:
-5.4483
EPS:
-3.5259
순현금흐름:
$-196.04M
1주 성능:
+8.23%
1개월 성능:
+16.85%
6개월 성능:
+44.87%
1년 성능:
-55.84%
1일 변동 폭
$19.00
$19.80
1주일 범위
$17.67
$20.12
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
19.21 | 1.41B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 업그레이드 | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
Insider Sell: Matthias Bodenstedt Sells Shares of MoonLake Immun - GuruFocus
MoonLake Immunotherapeutics (MLTX) director granted options on 22,195 shares - Stock Titan
MoonLake (MLTX) CFO sells 17,876 shares in pre-set 10b5-1 plan - Stock Titan
MoonLake Immunotherapeutics (MLTX) director receives 22,195 stock options grant - Stock Titan
Director at MoonLake Immunotherapeutics (MLTX) gets 22,195-share option grant - Stock Titan
MoonLake Immunotherapeutics (MLTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MoonLake Immunotherapeutics - TradingKey
MoonLake Immunotherapeutics (MLTX) Institutional Confidence - TradingKey
MoonLake Immunotherapeutics (MLTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
MoonLake Immunotherapeutics (MLTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
MoonLake Immunotherapeutics (MLTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MoonLake Immunotherapeutics (MLTX) CSO sells 150,000 shares under 10b5-1 plan - Stock Titan
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
How (MLTX) Movements Inform Risk Allocation Models - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Celldex (CLDX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
[144] MoonLake Immunotherapeutics SEC Filing - Stock Titan
Why did MLTX stock rise after-hours today? - MSN
How Sonelokimab’s FDA Pre-BLA Milestone And EULAR Data At MoonLake Immunotherapeutics (MLTX) Has Changed Its Investment Story - simplywall.st
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MoonLake Immunotherapeutics (MLTX) Slides 1.7% as Biotech Sector Pressure Weighs, Support at $16.62 in FocusCommon Gap - newsline.com
InvestingPro Fair Value catches MoonLake before 63% biotech surge By Investing.com - Investing.com India
MoonLake (NASDAQ: MLTX) shareholders approve equity plan expansion and re-elect director - Stock Titan
MLTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $45 - GuruFocus
Why Did MLTX Stock Rise After-Hours Today? - Stocktwits
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
H.C. Wainwright reiterates Moonlake stock rating on axSpA data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Moonlake stock rating on axSpA data - Investing.com
MLTX Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates, Stock DeclinesLong-Term Guidance - newsline.com
MoonLake Immunotherapeutics (MLTX) Valuation After FDA Progress On Sonelokimab Draws Fresh Investor Attention - simplywall.st
Trading Systems Reacting to (MLTX) Volatility - Stock Traders Daily
MoonLake Immunotherapeutics CFO Trims His Stake. Should Investors Be Concerned? - AOL.com
MoonLake earnings in focus: BLA path for sonelokimab takes center stage - Investing.com
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout
MoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA Progress - Insider Monkey
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):